| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:CLK2_MARS |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: CLK2_MARS | KinaseFusionDB ID: KFG1334 | FusionGDB2.0 ID: KFG1334 | Hgene | Tgene | Gene symbol | CLK2 | MARS | Gene ID | 9894 | 84174 | |
| Gene name | Src like adaptor 2 | |||||||||||
| Synonyms | C20orf156|MARS|SLAP-2|SLAP2 | |||||||||||
| Cytomap | 20q11.23 | |||||||||||
| Type of gene | protein-coding | |||||||||||
| Description | src-like-adapter 2Src-like adapter protein-2modulator of antigen receptor signaling | |||||||||||
| Modification date | 20240305 | |||||||||||
| UniProtAcc | P49760 | P56192 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000355560, ENST00000361168, ENST00000368361, ENST00000536801, ENST00000497188, | ENST00000262027, ENST00000315473, ENST00000447721, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CLK2 [Title/Abstract] AND MARS [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CLK2(155238084)-MARS(57881813), # samples:2 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | MARS | GO:0000122 | negative regulation of transcription by RNA polymerase II | 11696592 |
| Tgene | MARS | GO:0042110 | T cell activation | 11891219 |
| Tgene | MARS | GO:0050849 | negative regulation of calcium-mediated signaling | 11696592 |
| Kinase Fusion gene breakpoints across CLK2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across MARS (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-FX-A2QS-01A | CLK2 | chr1 | 155238084 | MARS | chr12 | 57881813 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:155238084/:57881813) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CLK2 | MARS |
| FUNCTION: Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Acts as a suppressor of hepatic gluconeogenesis and glucose output by repressing PPARGC1A transcriptional activity on gluconeogenic genes via its phosphorylation. Phosphorylates PPP2R5B thereby stimulating the assembly of PP2A phosphatase with the PPP2R5B-AKT1 complex leading to dephosphorylation of AKT1. Phosphorylates: PTPN1, SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Phosphorylates PAGE4 at several serine and threonine residues and this phosphorylation attenuates the ability of PAGE4 to potentiate the transcriptional activator activity of JUN (PubMed:28289210). {ECO:0000269|PubMed:10480872, ECO:0000269|PubMed:19168442, ECO:0000269|PubMed:28289210, ECO:0000269|PubMed:8910305, ECO:0000269|PubMed:9637771}. | FUNCTION: Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA (PubMed:11714285). Plays a role in the synthesis of ribosomal RNA in the nucleolus (PubMed:10791971). {ECO:0000269|PubMed:10791971, ECO:0000269|PubMed:11714285, ECO:0000269|PubMed:33909043}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CLK2_MARS |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| CLK2 | P49760 | human | PAGE4 | O60829 | S7 | _MSARVRsRsRGrGD | GAGE |
| CLK2 | P49760 | human | PAGE4 | O60829 | S73 | MDLEKtRsERGDGsD | GAGE |
| CLK2 | P49760 | human | PTPN1 | P18031 | S243 | DKRkDPssVDIkKVL | Y_phosphatase |
| CLK2 | P49760 | human | PAGE4 | O60829 | S79 | RsERGDGsDVKEKtP | GAGE |
| CLK2 | P49760 | human | PAGE4 | O60829 | T71 | QEMDLEKtRsERGDG | GAGE |
| CLK2 | P49760 | human | PAGE4 | O60829 | T85 | GsDVKEKtPPNPKHA | GAGE |
| CLK2 | P49760 | human | PTPN1 | P18031 | S50 | RNRyRDVsPFDHsRI | Y_phosphatase |
| CLK2 | P49760 | human | PAGE4 | O60829 | T94 | PNPKHAKtKEAGDGQ | GAGE |
| CLK2 | P49760 | human | PAGE4 | O60829 | T51 | PGQEREGtPPIEERK | GAGE |
| CLK2 | P49760 | human | PAGE4 | O60829 | S9 | SARVRsRsRGrGDGQ | GAGE |
| CLK2 | P49760 | human | PTPN1 | P18031 | S242 | MDKRkDPssVDIkKV | Y_phosphatase |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| CLK2 | ID | Description | 0.00e+00 |
| CLK2 | GO:0060397 | growth hormone receptor signaling pathway via JAK-STAT | 1.58e-02 |
| CLK2 | GO:1903897 | regulation of PERK-mediated unfolded protein response | 1.58e-02 |
| CLK2 | GO:2000644 | regulation of receptor catabolic process | 1.58e-02 |
| CLK2 | GO:0030948 | negative regulation of vascular endothelial growth factor receptor signaling pathway | 1.58e-02 |
| CLK2 | GO:0048012 | hepatocyte growth factor receptor signaling pathway | 1.58e-02 |
| CLK2 | GO:1900103 | positive regulation of endoplasmic reticulum unfolded protein response | 1.58e-02 |
| CLK2 | GO:0035791 | platelet-derived growth factor receptor-beta signaling pathway | 1.58e-02 |
| CLK2 | GO:1903894 | regulation of IRE1-mediated unfolded protein response | 1.58e-02 |
| CLK2 | GO:1900102 | negative regulation of endoplasmic reticulum unfolded protein response | 1.58e-02 |
| CLK2 | GO:0036499 | PERK-mediated unfolded protein response | 1.58e-02 |
| CLK2 | GO:1903427 | negative regulation of reactive oxygen species biosynthetic process | 1.58e-02 |
| CLK2 | GO:0036498 | IRE1-mediated unfolded protein response | 1.58e-02 |
| CLK2 | GO:1902236 | negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1.58e-02 |
| CLK2 | GO:0046628 | positive regulation of insulin receptor signaling pathway | 1.58e-02 |
| CLK2 | GO:0060396 | growth hormone receptor signaling pathway | 1.58e-02 |
| CLK2 | GO:0071378 | cellular response to growth hormone stimulus | 1.58e-02 |
| CLK2 | GO:1900078 | positive regulation of cellular response to insulin stimulus | 1.58e-02 |
| CLK2 | GO:0032801 | receptor catabolic process | 1.58e-02 |
| CLK2 | GO:0061098 | positive regulation of protein tyrosine kinase activity | 1.58e-02 |
| CLK2 | GO:1900101 | regulation of endoplasmic reticulum unfolded protein response | 1.58e-02 |
| CLK2 | GO:0035335 | peptidyl-tyrosine dephosphorylation | 1.58e-02 |
| CLK2 | GO:0043507 | positive regulation of JUN kinase activity | 1.58e-02 |
| CLK2 | GO:1902235 | regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1.58e-02 |
| CLK2 | GO:0030947 | regulation of vascular endothelial growth factor receptor signaling pathway | 1.58e-02 |
| CLK2 | GO:1905898 | positive regulation of response to endoplasmic reticulum stress | 1.58e-02 |
| CLK2 | GO:0060416 | response to growth hormone | 1.58e-02 |
| CLK2 | GO:0046627 | negative regulation of insulin receptor signaling pathway | 1.58e-02 |
| CLK2 | GO:0140467 | integrated stress response signaling | 1.58e-02 |
| CLK2 | GO:1900077 | negative regulation of cellular response to insulin stimulus | 1.58e-02 |
| CLK2 | GO:0043506 | regulation of JUN kinase activity | 1.58e-02 |
| CLK2 | GO:0060338 | regulation of type I interferon-mediated signaling pathway | 1.58e-02 |
| CLK2 | GO:1903426 | regulation of reactive oxygen species biosynthetic process | 1.58e-02 |
| CLK2 | GO:1903573 | negative regulation of response to endoplasmic reticulum stress | 1.58e-02 |
| CLK2 | GO:0006984 | ER-nucleus signaling pathway | 1.59e-02 |
| CLK2 | GO:0001881 | receptor recycling | 1.59e-02 |
| CLK2 | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 1.61e-02 |
| CLK2 | GO:0043407 | negative regulation of MAP kinase activity | 1.63e-02 |
| CLK2 | GO:0061097 | regulation of protein tyrosine kinase activity | 1.72e-02 |
| CLK2 | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 1.72e-02 |
| CLK2 | GO:1903409 | reactive oxygen species biosynthetic process | 1.72e-02 |
| CLK2 | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 1.76e-02 |
| CLK2 | GO:0070059 | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 1.83e-02 |
| CLK2 | GO:0046626 | regulation of insulin receptor signaling pathway | 1.90e-02 |
| CLK2 | GO:1900076 | regulation of cellular response to insulin stimulus | 1.91e-02 |
| CLK2 | GO:0043112 | receptor metabolic process | 1.92e-02 |
| CLK2 | GO:0030968 | endoplasmic reticulum unfolded protein response | 1.93e-02 |
| CLK2 | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 1.94e-02 |
| CLK2 | GO:0060337 | type I interferon-mediated signaling pathway | 1.97e-02 |
| CLK2 | GO:1905897 | regulation of response to endoplasmic reticulum stress | 1.97e-02 |
Top |
Related Drugs to CLK2_MARS |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning CLK2-MARS and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CLK2_MARS |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |